Patent Issued for Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof (USPTO 11773106).
| Předmět: | |
|---|---|
| Zdroj: | Pharma Business Week; 10/27/2023, p2275-2275, 1p |
| Abstrakt: | Initial treatment of the musculoskeletal symptoms is composed of nonsteroidal anti-inflammatory drugs (NSAIDs) and local corticosteroid injections, while topical therapies are used for the initial treatment of psoriasis. To date, other than NSAIDs, there have been no oral targeted therapies approved for the treatment of ankylosing spondylitis (AS) or non-radiographic axSpA. [Extracted from the article] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|